Form 4: Sangamo Therapeutics Executive Receives Stock Options

Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics, was granted stock options for 225,000 shares.

Summary

• Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics, Inc., was granted stock options on April 1, 2026.
• The options are for 225,000 shares of common stock with an exercise price of $0.2601 per share.
• The options have an expiration date of March 31, 2036.
• Vesting occurs in tranches: one-quarter vests on the first anniversary of the grant date, with the remainder vesting in 24 equal monthly installments thereafter.
• Vesting is contingent upon continued service with the company.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard executive compensation event (stock option grant) rather than a significant financial or strategic announcement.

Positives

• Grant of stock options to a key executive, indicating a potential alignment of executive interests with shareholder value.
• The significant number of options granted (225,000) suggests a substantial incentive for the Head of Research & Technology.
• The long expiration date (March 31, 2036) provides a long-term incentive structure.

Negatives

• The filing does not contain any negative information.

Risks

• Vesting is subject to the Reporting Person's Continuous Service, meaning departure from the company before full vesting would result in forfeiture of unvested options.
• The value of the options is dependent on the future stock price performance of Sangamo Therapeutics.

Future Outlook

The future outlook is tied to the vesting schedule of the stock options and the company's stock performance, which will determine the ultimate value realized by the executive.

Industry Context

StockSavvy.ai notes that the granting of stock options to key research and technology personnel is a common practice in the biotechnology and pharmaceutical sectors to attract, retain, and incentivize talent focused on innovation and long-term development.

Stakeholder Impact

• Shareholders: The grant of options aligns executive incentives with potential future stock price appreciation, but also represents potential dilution if options are exercised.
• Employees: May signal the company's commitment to retaining key talent in research and technology.
• Management: Directly benefits from the potential increase in the company's stock value.

Next Steps

• Continued service by Gregory D. Davis to meet vesting requirements.
• Monitoring of Sangamo Therapeutics' stock performance to assess the value of the granted options.

Key Dates

Keywords

Sangamo Therapeutics, SGMO, Form 4, Stock Options, Executive Compensation, Insider Trading, Beneficial Ownership, Gregory D. Davis, Vesting Schedule